title: Cox-2 deletion in myeloid and endothelial cells, but not in epithelial cells, exacerbates murine colitis.
abstract: Patients with inflammatory bowel diseases are at increased risk for colorectal cancer. Pharmacological inhibition of cyclooxygenase (COX) function exacerbates symptoms in colitis patients. Animal models of colitis using Cox-2-knockout mice and COX inhibitors also indicate that COX-2 has a protective role against colon inflammation. However, because conventional Cox-2 deletion and COX-2 inhibitors eliminate COX-2 function in all cells, it has not been possible to analyze the role(s) of COX-2 in different cell types. Here, we use a Cox-2(flox) conditional knockout mouse to analyze the role of COX-2 expression in distinct cell types in the colon in response to dextran sulfate sodium (DSS)-induced colitis. We generated Cox-2 conditional knockouts in myeloid cells with LysMCre knock-in mice, in endothelial cells with VECadCreERT2 transgenic mice and in epithelial cells with VillinCre transgenic mice. When treated with DSS to induce colitis, both myeloid cell-specific and endothelial cell-specific Cox-2-knockout mice exhibited greater weight loss, increased clinical scores and decreased epithelial cell proliferation after DSS injury when compared with littermate controls. In contrast, epithelial-specific Cox-2 knockouts and control littermates did not differ in response to DSS. These results suggest that COX-2 expression in myeloid cells and endothelial cells, but not epithelial cells, is important for protection of epithelial cells in this murine colitis model.
authors.affiliation: Department of Molecular and Medical Pharmacology, Department of Biological Chemistry, Molecular Biology Institute, and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
authors.forename: Tomo-O
authors.initials: TO
authors.lastname: Ishikawa
authors.forename: Masanobu
authors.initials: M
authors.lastname: Oshima
authors.forename: Harvey R
authors.initials: HR
authors.lastname: Herschman
mesh_terms: D000818:Animals; D017209:Apoptosis; D015139:Blotting, Southern; D015153:Blotting, Western; D049109:Cell Proliferation; D003092:Colitis / Q000201:enzymology* / Q000209:etiology / Q000473:pathology; D003106:Colon / Q000166:cytology; D051546:Cyclooxygenase 2 / Q000502:physiology*; D016264:Dextran Sulfate / Q000633:toxicity; D004195:Disease Models, Animal; D042783:Endothelial Cells / Q000187:drug effects / Q000201:enzymology*; D004847:Epithelial Cells / Q000187:drug effects / Q000201:enzymology*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D019426:Integrases / Q000378:metabolism; D008099:Liver / Q000166:cytology; D008156:Luciferases / Q000378:metabolism; D017737:Macrophages, Peritoneal / Q000166:cytology / Q000187:drug effects / Q000201:enzymology; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D022423:Myeloid Cells / Q000187:drug effects / Q000201:enzymology*
chemical_list: D016264:Dextran Sulfate; D008156:Luciferases; C077623:Ptgs2 protein, mouse; D051546:Cyclooxygenase 2; C045073:Cre recombinase; D019426:Integrases